Quotient Clinical Receives MHRA Supplementary Accreditation
News Jul 10, 2009
Quotient Clinical has announces that it has been awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range of Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.
The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximize subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.
Mark Egerton, Managing Director of Quotient Clinical comments, “Our MHRA Supplementary Accreditation provides volunteers and sponsors with additional reassurance of the high standards we apply in performing clinical studies. This award acknowledges our continued commitment to quality and safety and underpins our status as one of the leading clinical units in Europe.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019